Effect of triamcinolone acetonide-loaded nanoparticles on diabetic retinopathy in rats
Triamcinolone acetonide acetate (TAA)-loaded nanostructured lipid carriers (NLC) were prepared to investigate their transdermal absorption in vitro and establish a diabetic retinopathy (DR) rat model. To evaluate the effect of triamcinolone acetonide-loaded nanoparticle capsules on improving the structure of the retina and pancreas, we measured blood glucose levels and investigated the pathological changes in the retina and pancreas. The effect of triamcinolone acetonide-loaded nanoparticle capsules on the morphology of the retina and pancreas of the rats with DR was determined and compared among the normal group, model control group, positive control group, and triamcinolone acetonide-loaded nanoparticle group. After treatment with triamcinolone acetonideloaded nanoparticle capsules for 2 months, the blood glucose and glycosylated hemoglobin levels were significantly lower (P < 0.01) and the pathological changes were less severe in the triamcinolone acetonide-loaded nanoparticle group than in the model control group. In addition, the arrangement of the photoreceptor cell layers in the retina was organized, intracellular and extracellular edema in each layer was reduced compared with that in the model control group, the capillary lumen was not occluded, and the peripheral cells were slightly edematous in the triamcinolone acetonide-loaded nanoparticle group. Triamcinolone acetonide-loaded nanoparticle capsules could effectively reduce the blood glucose and glycosylated hemoglobin levels and improve the structure of the retina and pancreas in the rats with DR.